PRO51 COST-EFFECTIVENESS AND BUDGET IMPACT OF ONASEMNOGENE ABEPARVOVEC FOR SPINAL MUSCULAR ATROPHY TYPE 1: POST-HOC ANALYSIS OF A MODEL DEVELOPED BY ICER
Abstract
Authors
O. Dabbous R. Dean R. Arjunji D.M. Sproule D.E. Feltner D.C. Malone